106 pharmaceutical companies announced the performance of listed companies
According to incomplete statistics of E drug managers, as of January 13, a total of 106 listed companies listed on health and medical performance notice, of which pre-reduction and pre-losing companies a total of 10, pre-profit or pre- Increase the company a total of 80. Fan billion medicine, health yuan, Livzon Group, the new and into, Shanghai Lai Shi, Xin Li Tai, Biokang shares and Ruikang pharmaceutical companies are expected to net profit of 1 billion yuan the above.
Among all the pre-increased listed companies, Berry is expected to increase the most, and the net profit attributable to shareholders of listed companies is expected to increase by 5594.6% to 6311.29% in 2017. Berry said that on August 10, 2017, the company Major asset restructuring project completed in the third quarter Berry and Kang will become the financial parent company, the company's financial data merger, the company's share capital from 151,200,000 to 35,4605,865. According to the first three quarters of 2017 Berry And health has achieved financial data, the estimated full year 2017 the company will achieve net profit of 230 million -26,000 million.
Last year, Berry Gene and Huada Gene have landed in the capital market one after another medicine health Listed companies the fastest breaking 100 billion market capitalization record.Beige not long ago, the main body of the market Peiqi stripped of high investment, risk, return on the small tumor business, intended to optimize the financial statements in order to complete the agreement on gambling.
Nine companies such as Tiger, Zixin, Jieshi, Yaobao, Runda, Health yuan, Yongan, Livzon and Yi-sheng are all expected to report an increase of over 100% in net profit. Among them, the net profit of the annual report is expected to increase Yabao Pharmaceutical largest, up 788% -818%. Ya Bao Pharmaceutical said the pre-increase due to the company's key products, high gross profit product sales revenue due.
Watson Biologicals and Jiuan Medical are two of the top-100 losers in the list of 105 listed companies. Net profit attributable to shareholders of the listed company was -864.28% -857.18% and -1134.63% -996.68%, respectively.
The main businesses of Jiu An Medical include the research and development, production and sales of home medical and health electronic products, technical services and the establishment of a "Mobile Internet + Health Management Cloud Platform." The main products cover blood pressure, blood glucose, blood oxygen, electrocardiogram, heart rate, body weight, Fat, sleep, exercise and other areas of the more complete personal health wearable device product line.
Despite the "good times" of policy support, the performance of Jiu'an Medical has not been very good in recent years. According to the published results, the revenue of Jiu'an Medical from 2014 to 2016 was 425 million yuan and 398 million respectively Yuan, 420 million yuan, respectively, net profit of 10,197,500 yuan, a loss of 151 million yuan, 14,497,900 yuan.
For the possible substantial changes in net profit in 2017, Jiu An Medical indicated that during the reporting period, the Company will continue to focus on 'entering wearable devices and smart hardware into the field of mobile medical and health big data, and further establishing a healthy ecosystem around users 'Strategy to build an integrated service model of hardware and software innovation, the previous raise investment project will continue to gradually build the company to mobile medical transformation has entered a crucial stage, the need to continue to increase R & D investment.
Watson's latest revised 2017 performance forecast, net profit of the estimated loss has risen to a maximum of 538 million yuan, but previously announced the preliminary performance forecast, or profit of 30 million yuan to 50 million yuan.
Watson is a typical representative of pharmaceutical listed companies relying on non-stop mergers and acquisitions to achieve the industrial layout. However, while "buying growth", the original contribution of the business is getting lower and lower, even negative.
Watson's bio-performance deteriorated since the merger in 2012. Net profit fell 79.43% YoY in 2013 and net profit was 143 million in 2014. However, if Watson sold 634.8 million shares of Daan Pharmaceutical for sale, Yuan income, will face the loss of fate.In 2015, Watson biological huge loss of 841 million, of which provision of 4.8 billion impairment of goodwill, in 2016 the company relies on the sale of assets so that performance turnaround.
Watson said the performance correction is due to the transfer of assets did not meet the performance of Daan, Hebei, the company will bear the corresponding liability for the loss is expected to form the company in 2017 attributable to shareholders of listed companies net profit loss of 456.65 million yuan; due to the company debt to equity plan is not implemented The increase in finance costs and the increase in provision for bad debts of accounts receivable resulted in an increase of RMB 110.04 million in net profit loss attributable to shareholders of the listed company in 2017.
The revised results undoubtedly exceeded market expectations, however, sharply lower the performance at the same time, Watson Biologicals also released the company in research 13 varieties of pneumococcal polysaccharide conjugate vaccine, the latest progress.
Watson Biologicals said that the 13-valent vaccine clinical trial phase III statistical analysis showed that 13-valent vaccine phase III clinical trials of the safety and immunogenicity results have fully met the clinical trial pre-set evaluation standard , Marking the success of phase III clinical trials of the 13-valent pneumococcal conjugate vaccine jointly developed by the company and its subsidiary Yuxi Watson Biotechnology Co., Ltd. with independent intellectual property rights. In addition, the Company will also become the second phase III clinical trial in the world after Pfizer Experiment to get a successful 13-valent vaccine enterprise.
Watson said that the clinical research work on the 13-valent vaccine will not have a significant impact on the company's recent performance in the final phase of clinical research, but once the vaccine is approved for sale, it will have a huge positive impact on the company's future performance. However, Vaccine for new drug production and application drug The progress of review and approval still has some uncertainty.
Dongxing Securities pointed out that Watson Biological currently has 5 varieties, in addition to the clinical end of the 13-valent vaccine, the 23-valent pneumonic polysaccharide vaccine has been marketed; bivalent HPV in the clinical phase III ending stage, the probability will be listed in 2019 sales; Trastuzumab and infliximab are in Phase III clinical phase and are expected to be listed by 2020. Dongxing Securities believes that according to the current product line progress of Watson Biology, 2017 is the end of the downturn and also a full-blown performance outbreak The starting point.
